J&J Innovation unveils 17 deals

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) announced 17 new collaborations running the gamut from disease biology research to studying the real-world use of approved drugs.

Several early research collaborations are aimed at understanding the causes or underlying biology of diseases, including the first research collaboration announced for the Disease Interception Accelerator (DIA), operated by J&J's Janssen Research & Development LLC unit. Janssen and Washington University in St. Louis (St. Louis, Mo.) will research the role of antigen-presenting cells in the onset of Type I diabetes. The DIA's mission is to detect and intercept diseases before they start (see BioCentury, March 2). ...